首页> 外文OA文献 >Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates▿
【2h】

Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates▿

机译:单独或与RTS,S / AS01B疫苗同时给予恒河猴的恶性疟原虫肝阶段抗原1佐剂AS01B的疫苗的安全性和免疫原性的临床前评价▿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Several lines of evidence suggest that targeting pre-erythrocytic-stage parasites for malaria vaccine development can provide sterile immunity. The objectives of this study were (i) to evaluate preclinically the safety and immunogenicity of a new recombinant pre-erythrocytic-stage antigen, liver-stage antigen 1 (LSA1), in nonhuman primates; and (ii) to investigate the potential for immune interference between LSA1 and the leading malaria vaccine candidate, RTS,S, by comparing the immune responses after single-antigen vaccination to responses after simultaneous administration of both antigens at separate sites. Using a rhesus monkey model, we found that LSA1 formulated with the GlaxoSmithKline proprietary adjuvant system AS01B (LSA1/AS01B) was safe and immunogenic, inducing high titers of antigen-specific antibody and CD4+ T-cell responses, as monitored by the production of interleukin-2 and gamma interferon, using intracellular cytokine staining. RTS,S/AS01B vaccination was well tolerated and demonstrated robust antibody and moderate CD4+ T-cell responses to circumsporozoite protein (CSP) and HBsAg. Positive CD8+ T-cell responses to HBsAg were detected, whereas the responses to CSP and LSA1 were negligible. For both LSA1/AS01B and RTS,S/AS01B, no statistically significant differences were observed between individual and concurrent administration in the magnitude or duration of antibody and T-cell responses. Our results revealed that both pre-erythrocytic-stage antigens were safe and immunogenic, administered either separately or simultaneously to rhesus monkeys, and that no significant immune cross interference occurred with concurrent separate-site administration. The comparison of the profiles of immune responses induced by separate-site and single-site vaccinations with LSA1 and RTS,S warrants further investigation.
机译:有几条证据表明,针对疟疾疫苗开发的针对红细胞生成前阶段的寄生虫可以提供无菌免疫。这项研究的目的是(i)在非人灵长类动物中临床前评估新的重组红细胞前阶段抗原肝阶段抗原1(LSA1)的安全性和免疫原性; (ii)通过比较单抗原疫苗接种后的免疫应答与在不同部位同时施用两种抗原后的应答,来研究LSA1与主要的疟疾疫苗候选者RTS,S之间的免疫干扰潜力。使用恒河猴模型,我们发现用葛兰素史克专有佐剂系统AS01B(LSA1 / AS01B)配制的LSA1安全且具有免疫原性,可诱导高滴度的抗原特异性抗体和CD4 + T细胞反应,如白介素的产生所监测-2和γ干扰素,使用细胞内细胞因子染色。对RTS,S / AS01B疫苗的耐受性良好,证明对环子孢子蛋白(CSP)和HBsAg具有强力抗体和中等CD4 + T细胞反应。检测到对HBsAg的阳性CD8 + T细胞应答,而对CSP和LSA1的应答可忽略不计。对于LSA1 / AS01B和RTS,S / AS01B,在抗体和T细胞反应的大小或持续时间方面,在个体和同时给药之间均未观察到统计学上的显着差异。我们的研究结果表明,两种促红细胞生成前阶段的抗原都是安全且具有免疫原性的,可以分别或同时施用于恒河猴,并且同时进行分部位施药不会产生明显的免疫交叉干扰。 LSA1和RTS,S分别和单点疫苗接种诱导的免疫应答特征的比较值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号